German Pharma-Park Marburg, home to BioNTech, up for sale -sources
Reuters
Published Jul 22, 2021 10:46AM ET
FRANKFURT (Reuters) - Pharma-Park Marburg, where German drugmaker BioNTech produces its COVID-19 vaccine, has been put up for sale in a potential 450 million euro ($531 million) deal, three people close to the matter said.
The biotech-focused industrial park, which also counts GSK, Healthineers and CSL (OTC:CSLLY) Behring as tenants, has been offered for sale by its owner Infrareal, they said.
Insurer Swiss Life and infrastructure investor Ancala are expected to submit binding bids in coming days, the people added.
Infrareal and Ancala were not immediately available for comment, while Swiss Life declined to comment.
Pharma-Park Marburg has annual earnings before interest, tax, depreciation and amortisation of about 25 million euros and could be valued at 400-450 million euros, the people said.
The industrial park covers an area of 67.4 hectares, and approximately 6,000 employees work there.
($1 = 0.8481 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.